Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 1,200.00 [1] Core Insights - The company reported a significant revenue and profit growth in Q1 2026, exceeding expectations, with a projected net profit of approximately HKD 36-38 billion, representing a strong performance in a challenging market environment for gold jewelry consumption [6][9] - The company achieved a remarkable revenue growth of 221% year-on-year in 2025, with online sales increasing by 341% and a notable expansion in both domestic and international markets, including the opening of its first store in Singapore [7][8] - The gross margin for 2025 was 37.6%, slightly down from the previous year due to rising gold prices, but operational leverage improvements led to a net profit margin increase to 17.8% [8] Financial Performance Summary - Revenue projections for the upcoming years are as follows: - 2025: RMB 27,303 million - 2026E: RMB 36,758 million - 2027E: RMB 44,427 million - 2028E: RMB 50,462 million - Net profit projections are: - 2025: RMB 4,868 million - 2026E: RMB 7,339 million - 2027E: RMB 9,012 million - 2028E: RMB 10,464 million - The company expects a strong growth trajectory with net profit growth rates of 230.45% for 2025 and 50.75% for 2026 [5][10] Market Position and Competitive Advantage - The company has established a competitive edge through its high-end branding and product offerings, which have been validated by strong sales performance and customer acquisition, including an increase of 260,000 new members in 2025 [6][9] - The company’s strategy focuses on maintaining a premium positioning in the market, leveraging innovative product designs and craftsmanship to lead industry development [9]

Investment Rating - The report maintains a "Buy" rating for ZTO Express (02057) [2][7] Core Insights - ZTO Express reported a revenue of 49.099 billion RMB for 2025, reflecting a year-on-year growth of 10.9%, while the adjusted net profit was 9.513 billion RMB, a decrease of 6.3% [7] - The company achieved a business volume of 10.558 billion parcels in Q4 2025, with a year-on-year growth of 9%, significantly exceeding industry growth rates [7] - ZTO Express emphasizes shareholder returns, committing to a target of at least 50% of adjusted net profit for comprehensive shareholder returns starting in 2026 [7] - The company has completed a share repurchase plan of 2 billion USD and has authorized an additional 1.5 billion USD repurchase plan valid for 24 months [7] - The report has raised profit forecasts for 2026-2028, expecting adjusted net profits of 11.127 billion, 12.604 billion, and 14.106 billion RMB respectively, with corresponding year-on-year growth rates of 16.97%, 13.27%, and 11.92% [7] Financial Data and Profit Forecast - Revenue projections for ZTO Express are as follows: - 2024: 44.281 billion RMB - 2025: 49.099 billion RMB - 2026E: 54.388 billion RMB - 2027E: 59.562 billion RMB - 2028E: 64.532 billion RMB [6][8] - Adjusted net profit forecasts are: - 2024: 10.151 billion RMB - 2025: 9.513 billion RMB - 2026E: 11.127 billion RMB - 2027E: 12.604 billion RMB - 2028E: 14.106 billion RMB [6][8] - The report indicates a projected PE ratio of 12x for 2026E, 10x for 2027E, and 9x for 2028E [7]

Investment Rating - The investment rating for the company is "Buy" [3][12]. Core Insights - The company is expected to achieve breakeven in 2026, with accelerated realization of asset and technology platform value; the target price has been raised to HKD 10.00, reflecting a potential upside of 155.2% from the current price of HKD 3.92 [2][8]. Financial Overview - Revenue projections for 2026 are estimated at RMB 680 million, representing a year-on-year growth of 545.4% [7][14]. - The net profit is expected to turn positive in 2026, with a forecasted net profit of RMB 259 million [7][14]. - The company has seen a significant reduction in losses, with the net loss expected to narrow to RMB 239 million in 2025 from RMB 319 million in 2024 [8][14]. - The average daily trading volume is 3.79 million shares, and the market capitalization is approximately HKD 2.66 billion [5]. Key Developments - The company has received approval for its product, 希维奥®, for the treatment of multiple myeloma in mainland China, and it is also included in healthcare plans in Taiwan and South Korea [8]. - The company is expected to benefit from a recent deal with UCB for the ATG-201 asset, which is projected to contribute USD 80 million in near-term payments [8]. - The management anticipates that the core clinical projects and several preclinical TCE projects will enter the IND stage, leading to increased R&D investments [8]. Valuation Adjustments - The DCF target price has been raised to HKD 10.00 from HKD 8.8, based on updated revenue and profit forecasts for 2026-27 [8][10]. - The company is entering a critical development phase with significant potential for valuation upside as mid-to-late stage assets progress into registration clinical trials [8].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 15.03 [6]. Core Insights - The company is expected to achieve revenue of RMB 79.07 billion, net profit attributable to shareholders of RMB 4.50 billion, and adjusted net profit of RMB 4.25 billion for the year 2025, reflecting a year-on-year change of -2.0%, +20.5%, and +14.1% respectively [1]. - In the second half of 2025, the company reported revenue of RMB 38.80 billion, net profit of RMB 2.23 billion, and adjusted net profit of RMB 2.13 billion, with year-on-year changes of -1.7%, +20.6%, and +16.3% respectively, indicating that revenue met expectations [1]. - The beverage and instant noodle segments faced revenue declines of -2.9% and -0.5% year-on-year, respectively, while the second half of 2025 showed a recovery in instant noodle revenue with a year-on-year increase of +1.5% [1][2]. - The company’s EBIT margin improved by 1.2 percentage points year-on-year, driven by controlled costs and effective promotional strategies [3]. Revenue and Profitability - The beverage segment's revenue for 2025 decreased by 2.9% to RMB 50.10 billion, while the instant noodle segment's revenue decreased by 0.5% to RMB 28.28 billion [2]. - The gross margin for 2025 increased by 1.7 percentage points to 34.8%, with the beverage and instant noodle segments achieving gross margins of 37.5% and 29.7%, respectively [3]. - The company’s net profit margin for 2025 increased by 1.2 percentage points to 5.7%, with an EBIT margin of 8.8% [3]. Future Outlook - The company anticipates that rising oil prices will negatively impact the costs of PET and palm oil in 2026, but aims to maintain profit margins through improved operational efficiency [3][4]. - The forecasted net profit for 2026 and 2027 is RMB 4.28 billion and RMB 4.63 billion, respectively, with an estimated EPS of RMB 0.76 and RMB 0.82 [4][9]. - The report suggests that the dividend payout ratio may remain at 100% for the next 2-3 years, considering the peak in capital expenditures has passed [1].

Investment Rating - The investment rating for Tencent Holdings is "Buy" (maintained) [1][9] Core Views - The report highlights strong revenue growth driven by new games, AI applications, and WeChat commercialization, with Q4 2025 revenue reaching 194.4 billion yuan (up 13% year-on-year) and net profit of 58.3 billion yuan (up 14% year-on-year) [3][4] - The company is increasing its investment in AI, planning to allocate over 36 billion yuan in 2026 for new AI product development, which is expected to enhance long-term growth potential [4] - Tencent's gaming segment shows robust performance with significant user engagement in new titles, supporting continued high growth in the gaming sector [5] Financial Summary and Valuation Metrics - Revenue projections for Tencent are as follows: - 2024A: 660.3 billion yuan - 2025A: 751.8 billion yuan - 2026E: 838.6 billion yuan - 2027E: 919.0 billion yuan - 2028E: 996.6 billion yuan - Net profit projections are: - 2024A: 194.1 billion yuan - 2025A: 224.8 billion yuan - 2026E: 243.6 billion yuan - 2027E: 264.0 billion yuan - 2028E: 298.6 billion yuan - The report indicates a projected P/E ratio of 16.4 for 2026, decreasing to 13.4 by 2028, reflecting expected growth in earnings [6]

Investment Rating - The investment rating for the company is "Buy" [2][19]. Core Insights - The company reported a revenue growth of 0.9% year-on-year in Q4 2025, with a total revenue of $963 million, marking a positive turnaround [3][9]. - The gross margin improved to 60.3%, benefiting from increased contributions from Tumi and direct-to-consumer (DTC) sales, as well as effective tariff hedging measures [9]. - The EBITDA margin reached 20.3%, indicating a sequential improvement of 4 percentage points, reflecting stable profitability [9]. - The company expects Q1 2026 sales to remain flat year-on-year due to the impact of the Middle East conflict, but anticipates potential positive growth in subsequent quarters [9]. Financial Summary - Projected revenues for 2026-2028 are $3.559 billion, $3.725 billion, and $3.901 billion, respectively, with growth rates of 1.7%, 4.7%, and 4.7% [5][11]. - The net profit for 2026 is estimated at $294 million, with a growth of 1.8% year-on-year, and projected to increase to $321 million and $347 million in 2027 and 2028, respectively [5][11]. - The company maintains a PE ratio of 9.56 for 2026, with a target price of HKD 23.48 based on a 15x PE multiple [9][11]. Regional Performance - In Q4 2025, the Asia region showed a revenue increase of 5.1% year-on-year, with significant improvements in China and South Korea, while North America experienced a decline of 2.8% primarily due to a drop in Mexico's revenue [9][11]. - TUMI brand achieved stable growth despite high base effects, with revenue growth of 3.6% year-on-year, supported by new product development and enhanced marketing efforts [9][11].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 20.62 [1][14]. Core Insights - The company reported total revenue of RMB 8.58 billion for 2H25, representing a year-on-year increase of 12.5%, which exceeded the consensus estimate of RMB 8.45 billion. The growth was attributed to a favorable pace of store expansion [6][10]. - The non-IFRS net profit was RMB 290 million, which fell short of the consensus estimate of RMB 340 million due to the company's proactive pricing strategies aimed at increasing market share and price reductions from leading upstream brands, impacting gross margin expansion [6][10]. - The management expects to maintain pricing investments in 2026, particularly in categories with relatively high gross margins, while acknowledging that some categories may be nearing price bottoms [6][10]. - The company is well-positioned to mitigate cost pressures from rising prices of tires and oils due to its leading market share [6][10]. - The company is focusing on standardizing service capabilities and maintaining a steady pace of store expansion to solidify user perception and increase market share [6][10]. Financial Performance - For the fiscal year 2025, the company is projected to achieve revenue of RMB 16.46 billion, with a growth rate of 11.54%. The net profit attributable to shareholders is expected to be RMB 420.39 million, reflecting a decline of 13.10% [5][21]. - The adjusted net profit for 2026 is forecasted to be RMB 740.63 million, with a growth rate of 5.79% [5][21]. - The adjusted EPS for 2026 is estimated at RMB 0.91, with a corresponding adjusted PE ratio of 11.72 [5][21]. Market Position and Strategy - The company has expanded its store count to 8,008, with a net addition of 1,134 stores year-on-year, achieving a coverage rate of 75% in county-level cities with over 20,000 passenger vehicles [8][10]. - The company’s operational efficiency has improved, with a reduction in the operating expense ratio to 23.6% due to careful expense management and efficiency enhancements from automation [9][10]. - The integration of AI technology into various aspects of the business is being actively pursued to enhance user experience and operational efficiency [9][10].

Investment Rating - The report maintains a "Buy" rating for ZTO Express (02057) [2][7] Core Insights - ZTO Express reported a revenue of 49.099 billion RMB for 2025, reflecting a year-on-year growth of 10.9%, while the adjusted net profit was 9.513 billion RMB, a decrease of 6.3% [7] - The company achieved a business volume of 10.558 billion parcels in Q4 2025, with a year-on-year growth of 9%, significantly outpacing industry growth [7] - ZTO Express emphasizes shareholder returns, committing to a target of at least 50% of adjusted net profit for comprehensive shareholder returns starting in 2026 [7] - The company has completed a share repurchase plan of 2 billion USD and has authorized an additional 1.5 billion USD repurchase plan valid for 24 months [7] - The report has raised profit forecasts for 2026-2028, expecting adjusted net profits of 11.127 billion, 12.604 billion, and 14.106 billion RMB respectively, with corresponding year-on-year growth rates of 16.97%, 13.27%, and 11.92% [7] Financial Data and Profit Forecast - Revenue projections for ZTO Express are as follows: - 2024: 44.281 billion RMB - 2025: 49.099 billion RMB - 2026E: 54.388 billion RMB - 2027E: 59.562 billion RMB - 2028E: 64.532 billion RMB [6][8] - Adjusted net profit forecasts are: - 2024: 10.151 billion RMB - 2025: 9.513 billion RMB - 2026E: 11.127 billion RMB - 2027E: 12.604 billion RMB - 2028E: 14.106 billion RMB [6][8] - The report indicates a projected PE ratio of 12x for 2026E, 10x for 2027E, and 9x for 2028E [7]

Investment Rating - The report maintains a BUY rating on Henlius Biotech with a target price of HK$99.78, reflecting a potential upside of 52.0% from the current price of HK$65.65 [1][3]. Core Insights - Henlius Biotech reported strong FY25 financial results, with total revenue of RMB6.67 billion, representing a year-on-year growth of 16.5%. Product sales reached RMB5.77 billion, exceeding previous estimates by approximately 7.9% [1][5]. - The company is expanding its global biosimilar footprint and forming new international partnerships, positioning itself as an innovative biologics powerhouse with competitive assets such as HLX43, HLX22, and serplulimab [1][5]. - Anticipated clinical and regulatory catalysts in 2026 are expected to further enhance the company's growth trajectory [1]. Financial Summary - FY25 revenue was RMB6,667 million, with a year-on-year growth of 16.5%. Net profit for FY25 was RMB827 million, showing a slight increase of 0.8% year-on-year [2][10]. - The earnings per share (EPS) for FY25 was reported at RMB1.52, with a price-to-earnings (P/E) ratio of 37.9 [2][10]. - R&D investments increased to RMB2.49 billion, a growth of 35.4% year-on-year, indicating a strong commitment to developing the next-generation pipeline [5][10]. Product Performance - Serplulimab, a key product, generated sales of RMB1.50 billion, reflecting a year-on-year growth of 14.0%. The foundational biosimilar franchise, including trastuzumab, achieved global sales of RMB2.97 billion, up 5.5% year-on-year [5][10]. - Overseas product sales doubled to approximately RMB260 million, marking a 100% year-on-year increase [5]. - HLX43, a leading PD-L1 ADC, is entering pivotal stages with promising early efficacy signals in NSCLC, and additional pivotal trials are expected to commence by 4Q26 [5][10]. Market Position and Valuation - The market capitalization of Henlius Biotech is approximately HK$35.68 billion, with an average turnover of HK$61.5 million over the past three months [3]. - The target price of HK$99.78 is derived from a discounted cash flow (DCF) analysis, with a weighted average cost of capital (WACC) of 9.13% and a terminal growth rate of 3.5% [6][8].

Investment Rating - The report maintains a "Buy" rating for the company [2][19] Core Insights - The company experienced a positive revenue growth in Q4 2025, with a revenue of $963 million, reflecting a year-on-year increase of 0.9% on a currency-neutral basis [3][9] - The company expects sales net revenue to remain flat year-on-year in Q1 2026 due to the impact of the Middle East conflict, but anticipates potential positive growth in subsequent quarters [3][9] Financial Summary - Total revenue projections for the company are as follows: - 2024A: $3,589 million - 2025A: $3,498 million - 2026E: $3,559 million - 2027E: $3,725 million - 2028E: $3,901 million - The company’s net profit is projected to be: - 2024A: $346 million - 2025A: $289 million - 2026E: $294 million - 2027E: $321 million - 2028E: $347 million - The company’s PE ratio is expected to decrease from 11.75 in 2024A to 8.11 in 2028E [5][11] Regional Performance - In Q4 2025, the Asia region showed strong growth with a year-on-year revenue increase of 5.1%, while North America experienced a decline of 2.8%, which improved to a growth of 8.2% when excluding Mexico [9][11] - The company’s brand performance in Q4 2025 showed TUMI achieving stable growth, while Samsonite and American Tourister improved their growth rates compared to Q3 [9][11] Future Outlook - The company plans to continue investing in product innovation and marketing to strengthen its competitive advantage [9][11] - The international complex situation will need to be monitored closely as it may impact future sales [3][9]